Award
NIH Reporter #5R43AI192105-02
Optimizing immunogenicity of novel Cryptosporidium vaccine candidates
Recipient
IMMPORT THERAPEUTICS, INC.
Award Amount
$300,000.00
Ceiling
$300,000.00
Awarded
September 14, 2026
Identifier
5R43AI192105-02
Development of a novel vaccine candidate for cryptosporidiosis by testing recombinant Cryptosporidium proteins with an adjuvant to stimulate immune responses in preclinical models.
Description
This project aims to formulate and test novel Cryptosporidium proteins combined with a potent adjuvant to stimulate mucosal and systemic immune responses. The study involves producing recombinant proteins, formulating vaccines with GLA-3M052 liposome adjuvant, and evaluating immunogenicity and protective efficacy in mouse models. The goal is to develop a vaccine candidate suitable for preclinical testing.